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Background:  Evidence-based, guideline-directed medical therapies (GDMT) for patients with heart failure (HF) and reduced left 
ventricular ejection fraction (HFrEF) are proven to significantly reduce morbidity and mortality. However, many HFrEF patients still remain at 
high risk for HF hospitalization and mortality despite GDMT treatment. The CHAMPION trial demonstrated that pulmonary artery pressure 
(PAP) monitoring significantly reduced HF hospitalizations in patients with reduced or preserved ejection fraction. We evaluated whether 
the benefits of PAP monitoring were also observed in HFrEF patients already being treated at baseline with GDMT at therapeutic doses.
methods:  CHAMPION enrolled 550 patients with NYHA class III HF who were hospitalized for HF in the previous year. All patients were 
managed according to HF standard of care (SOC) while physician access to daily PAP data was available in the Treatment group only to 
help further guide HF management decisions. HF hospitalizations and mortality were analyzed to assess effectiveness. HFrEF was defined 
as left ventricular ejection fraction ≤ 40%.
results:  456 HFrEF patients (83%) were enrolled in CHAMPION with an average follow-up of 17 months.
GDMT Class
PAP Monitoring 
(Treatment 
Group)
N=222
HF SOC (Control 
Group)
N=234
Total Daily 
Dose HF Hospitalizations Mortality
# (%) On 
Therapy at 
Baseline
# (%) On Therapy 
at Baseline
Mean
[1]
Hazard 
Ratio
(95% CI)
NNT 
[2] p-value [3]
Hazard 
Ratio
(95% CI)
NNT
[2]
p-value
[4]
ACE inhibitor
or ARB
173
(78%)
183
(78%) 19.6 mg
0.59
(0.46-
0.75)
4 <0.0001
0.48
(0.28-
0.82)
7 0.0056
Beta Blocker 206(93%)
220
(94%) 29.3 mg
0.66
(0.53-
0.81)
5 0.0001
0.59
(0.38-
0.92)
11 0.0190
ACE inhibitor
or ARB
&
Beta Blocker
163
(73%)
174
(74%)
19.8 mg
29.7 mg
0.57
(0.45-
0.74)
3 <0.0001
0.43
(0.24-
0.76)
7 0.0026
[1] ACE inhibitor or ARB doses are converted to enalapril equivalents. Beta blocker doses are converted to carvedilol equivalents. Mean 
total daily dose is from both Treatment and Control group HFrEF patients.
[2] number needed to treat (NNT) to prevent one event per year
[3] hazard ratio, 95% Confidence Interval, and p-value from Andersen-Gill model
[4] hazard ratio and 95% Confidence Interval from Cox regression and p-value from logrank test
conclusion:  PAP management in HFrEF patients already on GDMT at therapeutic doses still resulted in significant reductions in 
HF hospitalizations and mortality. Neurohormonal control combined with hemodynamic optimization through PAP management led to 
substantial incremental clinical benefit.
